Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05455619 | Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer(Amelia-1) | recruiting | Phase 1 / Phase 2 | 52 | SynDevRx, Inc.INDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07069595 | PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease(PREDICT-RD) | recruiting | Phase 2 | 78 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 22, 2026 |
| clinicaltrials |
| NCT07123649 | Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study(I-MAMMO) | recruiting | Phase 2 | 364 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07198581 | AI-Assisted Chemotherapy Side Effect Management(ALLIANCE) | recruiting | N/A | 174 | Incheon St.Mary's HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07546331 | Novel Body Composition Measurements in Association With Outcomes of Breast Reconstruction Reconstruction | recruiting | — | 40 | University of California, San FranciscoOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT04003038 | Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery | recruiting | N/A | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07218432 | A Study of the TheraBionic P1 Device in Breast Cancer | recruiting | N/A | 24 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07378306 | FMD and Neoadjuvant Chemo-immunotherapy in TNBC(FACT-TN) | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07542106 | Effectiveness of a Visual Biofeedback Program Versus Conventional Physiotherapy on Shoulder Mobility, Strength, and Function in Women After Breast Cancer Surgery | recruiting | N/A | 40 | University of ExtremaduraOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07542496 | Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease(PERTUREAL) | recruiting | — | 1,000 | Société Algérienne de Formation et Recherche en OncologieOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT04740697 | Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer(EUTACAM) | recruiting | N/A | 200 | Institut Claudius RegaudOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05491226 | Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation | recruiting | Phase 2 | 35 | Stephen ShiaoOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06134375 | A Study of Tetrathiomolybdate (TM) Plus Capecitabine | recruiting | Phase 1 / Phase 2 | 204 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07539038 | Effects of Physical Activity in Early Stage Hormone Receptor Positive Breast Cancer Patients | recruiting | — | 44 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07540533 | A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer(2025-370) | recruiting | Phase 2 | 92 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03448926 | The PREDICT Registry: | recruiting | — | 3,000 | PreludeDxINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05704062 | Quantitative MRI Assessment of Breast Cancer Therapy Response | recruiting | — | 135 | Corewell Health EastOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06042569 | Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial | recruiting | Phase 2 | 174 | City of Hope Medical CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06195709 | ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients(ECLECTIC) | recruiting | Phase 3 | 300 | Institut CurieOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06427226 | Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity | recruiting | Phase 2 | 46 | Tanta UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06492759 | High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer | recruiting | Phase 2 | 29 | Emory UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07294703 | Factors Associated With Breast Cancer Risks and Outcomes | recruiting | — | 750 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02918474 | Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer | recruiting | N/A | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05056818 | Comparison of Synthetic Mammography Versus Full-Field Digital Mammography in Image Interpretation and Performance Metrics | recruiting | — | 750 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05749588 | FUSCC Refractory TNBC Platform Study (FUTURE2.0) | recruiting | Phase 2 | 120 | Fudan UniversityOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06681064 | Breast Cancer Evolution During Neoadjuvant Systemic Therapy(BELIEVE) | recruiting | — | 500 | Royal Marsden NHS Foundation TrustOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07447414 | Luminal Breast Cancer Cryoablation(LUBRECA) | recruiting | N/A | 140 | Lucía Graña LópezOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07533123 | A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care | recruiting | Phase 3 | 364 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT00477100 | Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer | recruiting | — | 1,200 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05042687 | Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer | recruiting | N/A | 300 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06518382 | Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer Patients | recruiting | — | 10 | Giampaolo BianchiniOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07045311 | JS207 Combination Therapy in Triple-negative Breast Cancer | recruiting | Phase 2 | 80 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07532434 | A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer | recruiting | — | 480 | Peking University Third HospitalOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04342546 | Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction(PRETORIA) | recruiting | N/A | 250 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05095207 | Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 42 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05313191 | Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors(ReRT) | recruiting | N/A | 1,800 | The New York Proton CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05837455 | NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer | recruiting | Phase 2 | 81 | Washington University School of MedicineOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05874492 | Evaluation of the Medical Benefit of Spa Therapy on Fibrosis After Radiotherapy for Breast Cancer or UADT (Upper Aerodigestive Tract) Cancer(FIBROTHERME) | recruiting | N/A | 110 | Association Francaise pour la Recherche ThermaleOTHER | 2 | Apr 13, 2026 | clinicaltrials |
| NCT06810804 | A Phase IIa Study to Evaluate NBQ72S | recruiting | Phase 2 | 10 | Nantong Bencao Quadriga Medical Technology Co. Ltd.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07164976 | Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 86 | Nagoya City UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07524829 | Telenursing for the Early Detection and Management of Side Effects Associated With Cyclin-Dependent Kinase Inhibitors in Breast Cancer Patients | recruiting | N/A | 124 | Azienda Sanitaria Locale di AstiOTHER_GOV | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04841148 | Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer(PALAVY) | recruiting | Phase 2 | 96 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07227233 | Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.(AIM-BRIGHT) | recruiting | Phase 2 | 105 | University of California, San DiegoOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06915168 | CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer | recruiting | N/A | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07441460 | A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer | recruiting | Phase 3 | 1,800 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT03897270 | Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects | recruiting | N/A | 400 | Roswell Park Cancer InstituteOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06896474 | SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers(SDMPOSSIBLE) | recruiting | N/A | 402 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 22, 2026source: clinicaltrials